Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 152.29 -2.04 (-1.32%) Market Cap: 19.26 Bil Enterprise Value: 18.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Topline Results Transcript

Aug 03, 2022 / 12:00PM GMT
Release Date Price: $212.01 (+49.33%)
Operator

Welcome to the Alnylam Pharmaceuticals Conference Call to discuss the Positive Topline Results from the APOLLO-B Phase 3 study. (Operator Instructions)

I would now like to hand the conference over to the company. Please go ahead.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, our Chief Executive Officer; Akshay Vaishnaw, our President; Pushkal Garg, our Chief Medical Officer; and Tolga Tanguler, our Chief Commercial Officer.

Also joining us on the line and available for Q&A are Jeff Poulton, our Chief Financial Officer; Rena Denoncourt, Vice President, TTR Franchise Lead; and John Vest, Vice President of Clinical Research.

For those of you participating via conference call, the slides we've made available via webcast can also be accessed by going to the Investors page of our website, alnylam.com/events.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot